Altered Maternal Serum Matrix Metalloproteinases MMP-2, MMP-3, MMP-9, and MMP-13 in Severe Early- and Late-Onset Preeclampsia

Table 2

Matrix metalloproteinases: MMP-2, MMP-3, MMP-9, and MMP-13 levels in maternal serum samples in both preeclamptic groups of women and in healthy controls.

	MMP-2 (ng/mL)	MMP-3 (ng/mL)	MMP-9 (ng/mL)	MMP-13 (ng/mL)
The control group ()	195.30 ± 43.53; Median 189.95; (103.88–347.83)	29.23 ± 58.79; Median 16.749; (2.046–454.53)	1752.59 ± 901.54; Median 1605.75; (336.83–4569.2)	0.427 ± 0.228; Median 0.409; (0.014–1.047)
Statistical analysis, control-earlyPre
The group earlyPre ()	242.93 ± 68.64; Median 235.26 (136.88–466.90)	63.54 ± 71.58; Median 37.115; (13.65–314.14)	1450.12 ± 838.01; Median 1153.32; (243.68–3383.13)	0.590 ± 0.681; Median 0.407; (0.054–4.351)
Statistical analysis, earlyPre-latePre
The group latePre ()	234.39 ± 79.18; Median 219.17; (124.19–514.79)	27.91 ± 24.99; Median 18.04; (4.16–124.17)	1450.86 ± 1165.93; Median 1040.2; (325.07–6430.0)	0.482 ± 0.278; Median 0.385; (0.008–1,264)
Statistical analysis, control-latePre

Data presented as a mean ± SD. Statistical significance (); groups of studied pregnant women: control group: healthy normotensive pregnant women; earlyPre group: patients with pregnancy complicated by early-onset severe preeclampsia; latePre group: women with pregnancy complicated by late-onset severe preeclampsia.